Related Experiment Video

Updated: May 22, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

HIV/HCV coinfection: a new era of treatment

Liz Highleyman1

  • 1liz@hivandhepatitis.com

BETA : Bulletin of Experimental Treatments for AIDS : a Publication of the San Francisco AIDS Foundation
|May 10, 2012
PubMed

Insights

Direct-acting antiviral agents (DAAs) show promise for treating Hepatitis C virus (HCV) coinfection in people with HIV. Early data presented at CROI and IDSA suggest these new treatments are effective for HIV/HCV coinfected individuals.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Hepatitis C virus (HCV) infection can lead to severe liver disease, including cirrhosis, liver cancer, and liver failure.
  • HCV coinfection affects a significant portion of individuals with HIV, and HCV-related liver disease is a leading cause of mortality in this population, even with effective antiretroviral therapy (ART).
  • The recent approval of direct-acting antiviral (DAA) agents marks a significant advancement in HCV treatment strategies.

Purpose of the Study:

  • To present initial findings on the efficacy and safety of direct-acting antiviral (DAA) agents in patients coinfected with HIV and HCV.
  • To evaluate the impact of new HCV treatments in the context of ongoing HIV management.

Main Methods:

  • Data from studies investigating DAAs in HIV/HCV coinfected populations were presented.
  • Presentations were made at major infectious disease conferences, including the Conference on Retroviruses and Opportunistic Infections (CROI) and the Infectious Disease Society of America (IDSA) annual meeting in 2011.

Main Results:

  • Preliminary data indicated the effectiveness of DAAs in treating HCV in individuals with HIV.
  • The findings suggest a potential paradigm shift in managing HCV coinfection among people living with HIV.

Conclusions:

  • Direct-acting antiviral agents represent a groundbreaking therapeutic option for HIV/HCV coinfected individuals.
  • Further research and clinical application of DAAs are expected to improve outcomes for this vulnerable patient group.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...